Higher High-Density Lipoprotein Cholesterol - Good Omen, Bad Omen, or Not an Omen at All

John Wilkins; Anand Rohatgi

doi:10.1001/jamacardio.2022.5143

Higher High-Density Lipoprotein Cholesterol - Good Omen, Bad Omen, or Not an Omen at All

John Wilkins, Anand Rohatgi^*

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	273-274
Number of pages	2
Journal	JAMA cardiology
Volume	8
Issue number	3
DOIs	https://doi.org/10.1001/jamacardio.2022.5143
State	Published - Mar 8 2023

Funding

Conflict of Interest Disclosures: Dr Wilkins reported consulting fees from 3M. Dr Rohatgi reported grants and consulting fees from CSL Behring, advisory board fees from Horizon Therapeutics and Arrowhead Pharmaceuticals, grants from Quest Diagnostics, research collaboration from LabCorp, and consulting fees from HDL Diagnostics. No other disclosures were reported.

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1001/jamacardio.2022.5143

Cite this

@article{23e99b017de54918a052d32a0b9a71c9,

title = "Higher High-Density Lipoprotein Cholesterol - Good Omen, Bad Omen, or Not an Omen at All",

author = "John Wilkins and Anand Rohatgi",

note = "Funding Information: Conflict of Interest Disclosures: Dr Wilkins reported consulting fees from 3M. Dr Rohatgi reported grants and consulting fees from CSL Behring, advisory board fees from Horizon Therapeutics and Arrowhead Pharmaceuticals, grants from Quest Diagnostics, research collaboration from LabCorp, and consulting fees from HDL Diagnostics. No other disclosures were reported. ",

year = "2023",

month = mar,

day = "8",

doi = "10.1001/jamacardio.2022.5143",

language = "English (US)",

volume = "8",

pages = "273--274",

journal = "JAMA cardiology",

issn = "2380-6583",

publisher = "American Medical Association",

number = "3",

}

TY - JOUR

T1 - Higher High-Density Lipoprotein Cholesterol - Good Omen, Bad Omen, or Not an Omen at All

AU - Wilkins, John

AU - Rohatgi, Anand

N1 - Funding Information: Conflict of Interest Disclosures: Dr Wilkins reported consulting fees from 3M. Dr Rohatgi reported grants and consulting fees from CSL Behring, advisory board fees from Horizon Therapeutics and Arrowhead Pharmaceuticals, grants from Quest Diagnostics, research collaboration from LabCorp, and consulting fees from HDL Diagnostics. No other disclosures were reported.

PY - 2023/3/8

Y1 - 2023/3/8

UR - http://www.scopus.com/inward/record.url?scp=85149973974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85149973974&partnerID=8YFLogxK

U2 - 10.1001/jamacardio.2022.5143

DO - 10.1001/jamacardio.2022.5143

M3 - Comment/debate

C2 - 36652232

AN - SCOPUS:85149973974

SN - 2380-6583

VL - 8

SP - 273

EP - 274

JO - JAMA cardiology

JF - JAMA cardiology

IS - 3

ER -

Higher High-Density Lipoprotein Cholesterol - Good Omen, Bad Omen, or Not an Omen at All

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this